POEMs
Patient-Oriented Evidence That Matters

Left Atrial Appendage Closure Is Inferior to Best Medical Therapy for Patients With Atrial Fibrillation and High Bleeding and Stroke Risk

Mark H. Ebell, MD, MS,
Professor, Michigan State University, East Lansing; AFP Deputy Editor for Evidence-Based Medicine

American Family Physician. 2026;114(5):543B.

Author Disclosure: No relevant financial relationships.

CLINICAL QUESTION

In patients with atrial fibrillation and a high risk of stroke or bleeding, is left atrial appendage closure noninferior to best medical therapy (generally with a direct oral anticoagulant [DOAC])?

BOTTOM LINE

In patients with atrial fibrillation at high risk for major bleeding and stroke, best medical therapy (usually with a DOAC) is superior to left atrial appendage closure. The high cost of DOACs in the United States is a significant barrier for many patients. (Level of Evidence = 1b)

SYNOPSIS

Left atrial appendage closure is an alternative to DOACs in patients with atrial fibrillation and has been shown to be equivalent or superior to DOACs following catheter ablation and in patients undergoing cardiac surgery. In the German study, researchers identified patients with atrial fibrillation and a high risk of stroke (CHA2DS2-VASc [congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex (female)] score ≥ 2), high risk of bleeding (HAS-BLED [hypertension, abnormal kidney and liver function, stroke, bleeding risk, labile international normalized ratio, elderly (older than 65 years), drug and alcohol use] score ≥ 3), a history of major bleeding, or chronic kidney disease. At baseline, the 888 patients had a mean age of 78 years, 39% were female, 93.5% were White, 43% had a history of major bleeding, and 24% had chronic kidney disease. Groups were balanced, and analysis was by intention to treat. The primary outcome was a composite of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death adjudicated by a committee masked to the treatment assignment. Patients were randomized to receive left atrial appendage closure with one of three devices chosen by the physician (93% of these patients received a device) or best medical therapy (85% received a DOAC, 3% a vitamin K antagonist, 2.3% antiplatelet therapy, and 9.5% received no therapy or had missing information). In the device implantation group, dual antiplatelet therapy was recommended for 3 months. The median follow-up was 3 years, and the longest follow-up was 6.7 years.

The composite outcome occurred significantly more often in the left atrial appendage closure group (16.8 vs 13.3 events per 100 person-years; number needed to treat [NNT] = 29) in the primary intention-to-treat analysis and in the per-protocol analysis for only those patients who received the device or anti-thrombotic therapy (16.6 vs 12.5; NNT = 24). This was primarily driven by more major bleeding and more cardiovascular or unexplained deaths. All-cause mortality was not significantly higher (14.8% vs 13.5%). Hospitalization for bleeding or a cardiovascular event was significantly more common in the device group (53.0 vs 39.4 events per 100 person-years; NNT = 7).

Study Design: Randomized controlled trial (single-blinded)

Funding Source: Government

Allocation: Concealed

Setting: Outpatient (specialty)

Reference: Landmesser U, Skurk C, Kirchhof P, et al.; CLOSURE-AF Trial Investigators. Left atrial appendage closure or medical therapy in atrial fibrillation. N Engl J Med. 2026;394(13):1270-1280.

Editor’s Note: Dr. Ebell is cofounder and editor-in-chief of Essential Evidence Plus.

Mark H. Ebell, MD, MS, Professor, Michigan State University, East Lansing; AFP Deputy Editor for Evidence-Based Medicine

Author Disclosure: No relevant financial relationships.

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com​. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/Home/Loe​.

Primary Care Update, a free podcast focused on POEMs, is available on Apple Podcasts​ and Spotify​.

This series is coordinated by Natasha J. Pyzocha, DO, contributing editor.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.